In 1865 Armand Trousseau noted that unexpected and/or migratory thrombophlebitis could be a forewarning of an occult visceral malignancy. An analysis by Sack and colleagues in 1977 extended the term "Trousseau's Syndrome" to include chronic disseminated intravascular coagulopathy associated with microangiopathy, verrucous endocarditis and arterial emboli in patients with cancer, often occurring with mucin-positive carcinomas. In recent times the term has been ascribed to clinical situations ranging all the way from these classic descriptions, to any kind of coagulopathy occurring in the setting of any kind of malignancy. These multiple definitions of "Trousseau's Syndrome" are partly the consequence of multiple pathophysiological mechanisms that apparently contribute to the hypercoagulability associated with cancer. Even the classic syndrome appears likely to represent a spectrum of disorders, ranging from exaggerated fluid-phased thrombosis dependent on prothrombotic agents such as tissue factor to a platelet-and endothelium-based selectin-dependent microangiopathy associated with mucin-producing carcinomas, along with thrombin and fibrin production. Also considered here are recent hypotheses concerning genetic pathways within tumor cells that might trigger these thrombotic phenomena, and the reasons why therapy with heparins of various kinds remain the preferred treatment -likely because of their salutary actions on several of the proposed pathological mechanisms. overlapping hits. Such searches, along with review of web-based sources yields definitions of "Trousseau's Syndrome" ranging from "occurrence of thrombophlebitis migrans with visceral cancer"; and, "spontaneous recurrent or migratory venous thromboses and/or arterial emboli caused by nonbacterial thrombotic endocarditis in a patient with malignancy" -all the way to simply "carcinoma-induced coagulopathy"; "hypercoagulability syndrome associated with cancer"; "malignancy-related thromboembolism"; "idiopathic thromboembolism associated with cancer"; and, "malignancy-related hypercoagulability". Based on the actual history, it seems reasonable to restrict use of "Trousseau's Syndrome" to unexplained thrombotic events that precede the diagnosis of an occult visceral malignancy, and/or appear concomitantly with the tumor. As discussed below, even this restricted definition encompasses a spectrum of disorders, in which multiple over-lapping mechanisms are likely to be involved. . Such findings suggested that activators of fluid-phase coagulation were the key to the pathogenesis [9] [10] [11] [12] [13] [14] [15] [16] [17] . This review concludes that Trousseau's Syndrome is actually a spectrum of disorders, and considers additional molecular mechanisms that have more recently pointed to pathways for its initiation. This is done recognizing how little we still understand about this syndrome, and yet how important it is to seek a better understanding of it.
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For personal use only. on . by guest www.bloodjournal.org From 3 "Trousseau's Syndrome" is well-known to clinicians, partly because Armand Trousseau not only described it in 1865 1 -but also diagnosed the syndrome on himself two years later, succumbing shortly thereafter to a gastric cancer 2, 3 . The association between cancer and excessive blood coagulation remains well recognized, forming the basis of many reviews, monographs, symposia and international conferences. Most of these begin by mentioning
Trousseau and his eponymous syndrome. Trousseau made an astute clinical observation, noting that some patients who presented with unexpected, unusual or migratory thromboses later manifested a visceral malignancy. This description was refined and extended over the years, culminating in a classic review by Sack and colleagues 4 , in which Trousseau's Syndrome was reported as being frequently associated with chronic disseminated intravascular coagulopathy, platelet-rich microthrombi, microangiopathic hemolytic anemia, verrucous endocarditis, and thromboembolic problems related to these processes. In more recent times, many patients are diagnosed with "Trousseau's Syndrome" even if they do not manifest these classic features, and the definition has included those presenting primarily with uncomplicated lower limb deep venous thrombosis. The term is sometimes even applied to patients who already have an advanced malignancy, and then develop some form of thrombosis. While similar mechanisms may be operating, such advanced cases often have other reasons for a thrombotic tendency, such as immobility, dehydration, mechanical compression of veins, infectious processes, chemotherapy, etc.
What is "Trousseau's Syndrome"? Despite its frequent mention in reviews [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] , the term "Trousseau's Syndrome" is not in the MeSH headings of Medline/PubMed. Literature searching is confounded by the insistence of some journal editors on using "Trousseau syndrome" 18 . Thus, searching Pubmed for "Trousseau's syndrome" and "Trousseau syndrome" yields mostly nonFor personal use only. on . by guest www.bloodjournal.org From overlapping hits. Such searches, along with review of web-based sources yields definitions of "Trousseau's Syndrome" ranging from "occurrence of thrombophlebitis migrans with visceral cancer"; and, "spontaneous recurrent or migratory venous thromboses and/or arterial emboli caused by nonbacterial thrombotic endocarditis in a patient with malignancy" -all the way to simply "carcinoma-induced coagulopathy"; "hypercoagulability syndrome associated with cancer"; "malignancy-related thromboembolism"; "idiopathic thromboembolism associated with cancer"; and, "malignancy-related hypercoagulability". Based on the actual history, it seems reasonable to restrict use of "Trousseau's Syndrome" to unexplained thrombotic events that precede the diagnosis of an occult visceral malignancy, and/or appear concomitantly with the tumor. As discussed below, even this restricted definition encompasses a spectrum of disorders, in which multiple over-lapping mechanisms are likely to be involved.
Early Theories regarding Mechanisms of Trousseau's Syndrome. When thromboses occur
in the setting of occult carcinomas, it is reasonable to speculate that tumor products entering the bloodstream are primarily responsible. The association of the syndrome with mucin-producing carcinomas initially suggested that mucins were the underlying trigger 19 . Mucins are highly glycosylated secretory products of epithelial cells that become aberrantly glycosylated in carcinomas and then inappropriately secreted into the bloodstream [20] [21] [22] [23] [24] . 28, 29 -including instances when the primary tumor was extremely small, and yet able to induce major systemic thromboses 26 . Also described was a cysteine proteinase from carcinoma extracts, which directly activated Factor X [30] [31] [32] . Such findings suggested that activators of fluid-phase coagulation were the key to the pathogenesis [9] [10] [11] [12] [13] [14] [15] [16] [17] . This review concludes that Trousseau's Syndrome is actually a spectrum of disorders, and considers additional molecular mechanisms that have more recently pointed to pathways for its initiation. This is done recognizing how little we still understand about this syndrome, and yet how important it is to seek a better understanding of it.
Tissue Factor. In addition to cases of Trousseau's Syndrome involving carcinomas rich in TF, elevated TF expression by the associated angiogenic endothelium has been reported. Activated oncogenes (K-ras, EGFR, PML-RARA, and MET) or inactivated tumor suppressors (e.g., 53 or PTEN) also lead to an induction in TF levels and activity, which is postulated to promote not only hypercoagulability, but also tumor aggressiveness and angiogenesis [14] [15] [16] . The thrombin receptor (protease-activated receptor-1) is also upregulated in cancer cells expressing oncogenic K-ras 33 . The question arises as to how the tumor-derived TF becomes exposed to the fluid-phase coagulation system, starting with circulating factor VII. In classic studies, histological evidence of direct contact between a TF-rich tumor and the bloodstream seem to be associated with 15, 33 .
Regardless of the originating mechanisms, it is likely that conversion of Factor-VII to its active form (VIIa) in complex with TF triggers the production of other coagulation-related proteases, particularly FXa and FIXa. Factor Xa then works with FVa to cleave circulating prothrombin and generate thrombin -which is required not only to generate fibrin and activate platelets, but also to facilitate amplification through further generation of other active clotting factors such as FVIIIa and FXIa (see Figure 1 ). While all these mechanisms involving TF and thrombin seem reasonable, more studies are needed to directly demonstrate their role in patients with
Trousseau's Syndrome.
Tumor-Associated Cysteine Proteinase. As mentioned above, Falanga and Gordon 30 reported a cysteine protease ("cancer procoagulant" or CP) that directly activated factor X in the absence of factor VII, and this activity was later reported in many natural human tumors 38, 39 . However, there is some question as to whether this is due to contamination with traces of TF/VIIa complexes. A recent study of such preparations using anti-TF antibodies noted cross-reactive proteins 32 , and the authors concluded that "it seems possible that cancer procoagulant preparations contain proteins that have some epitopes similar to the epitopes recognized in [20] [21] [22] [23] [24] , and are often carriers of sialylated, fucosylated, sulfated glycans that can act as ligands for the selectins 41, 42 . Such selectin-mucin interactions seem to be involved in the hematogenous phase of tumor metastasis [42] [43] [44] [45] . Mixtures of these abnormal carcinoma mucins (and/or their proteolytic fragments) are also shed by tumors, and can be found in the bloodstream of cancer patients [46] [47] [48] [49] [50] [51] [52] [53] , where their levels are sometimes measured as prognostic markers. Thus, it remained reasonable to suggest that mucins are involved in Trousseau's Syndrome.
One way to eliminate contamination is to take advantage of the fact that tumor mucins contain heavily glycosylated segments that are resistant to denaturation, boiling, and even proteases. Thus, when human colon carcinomas xenograft extracts were treated with multiple enzymes (including broad spectrum proteases) followed by boiling and denaturation, the only 18 . These preparations were free of TF or endotoxin, and incapable of accelerating clotting in vitro. However, they rapidly induced disseminated platelet-rich microthrombi when injected intravenously into normal mice. These occurred even when animals were pretreated with amounts of hirudin sufficient to block in vivo thrombin formation (although as expected, the associated fibrin deposition did not occur). Moreover, this platelet aggregation was dependent on P-selectin and L-selectin, as determined using genetically-deficient mice 18 . This is consistent with prior findings that carcinoma mucins have binding sites for both and P-and L-selectin 42 . Further studies indicated a step-wise process in which the mucins initially activate leukocytes via L-selectin ligation, generating an as yet unknown mediator, which then cooperates with the mucins interacting with P-selectin on endothelium and/or platelets, ultimately generating the platelet-rich microthrombi (see Figure 1 ) -including fibrin deposition, via an as yet unknown mechanism. Interestingly, while the formation of the platelet clumps themselves could not be abrogated by thrombin inhibitors such as hirudin, it was efficiently blocked by heparin. This is consistent with the finding that heparin (at concentrations acceptable in clinical practice), is a potent inhibitor of Pand L-selectin interactions with natural or carcinoma ligands 42, 54, 55 .
The great majority of such injected carcinoma mucins were rapidly cleared by multiple glycan receptors in the mouse liver 56 . The small amounts surviving clearance were heavily sialylated, and presumably represented the fraction mediating the pathological reactions with platelets and leukocytes. Thus patients with carcinomas likely secrete large quantities of mucins into circulation, which are rapidly cleared -leaving behind only the proverbial "tip of the iceberg" in the bloodstream. The pathological processes triggered by such carcinoma mucins require not only altered glycosylation, but also inappropriate secretion into the vascular
Thus, mucins might also enter the bloodstream in non-malignant processes involving mucin-secreting organs. Could this help explain the high frequency of venous thrombosis in inflammatory bowel disease 57 ? Elevated levels of serum mucin antigens are also associated with hepatocellular disease and liver cirrhosis. As the liver itself does not produce mucins, this may represent failure of the mucin clearance system to remove the low levels of mucins that normally spill into the blood from hollow organs. This is also a potential explanation for the "false positive" tumor marker studies 58 , and the unexplained coagulopathies seen in patients with chronic liver disease 59 .
Mechanisms Involving Oncogene Activation. In 2005, Boccaccio et al. stated that Trousseau's
Syndrome had "so far resisted a mechanistic explanation" 60 . While this claim was at odds with prior literature, the authors did present a truly novel mechanism, using a mouse model in which targeting an activated human MET oncogene to adult mouse liver caused slowly progressing hepatocarcinogenesis, which was preceded and accompanied by a syndrome "manifesting first with blood hypercoagulation (venous thromboses), and then evolving towards fatal internal hemorrhages". Following up on these observations, these investigators demonstrated that the pathogenesis of this model syndrome was driven by the transcriptional response to the MET oncogene, especially involving upregulation of PAI-1 and cyclooxygenase-2 (COX-2) genes.
Since both molecules can theoretically support a thrombohemorrhagic phenotype, they concluded that they had found "direct genetic evidence for the long-sought-after link between oncogene activation and haemostasis". They later went on to point out that hypoxia could induce Met oncogene transcription, suggesting that this provided "a clinically important perspective on malignant invasion and metastasis" 61 . However, as with all earlier mechanisms described above, this one also requires validation in the natural clinical setting of patients with Trousseau's Syndrome.
A Spectrum of Overlapping Mechanisms in "Trousseau's Syndrome"? It is reasonable to
suggest that all these proposed mechanisms represent a range of overlapping pathways that contribute to varying extents towards the thromboembolic diathesis in patients with tumors (see While this is often not feasible, the one recurring theme in the literature is that heparin is the preferred treatment -and that specifically blocking factor Xa or thrombin is insufficient in many instances 4, [62] [63] [64] [65] [66] . Indeed, there are many reports of marked and even catastrophic acceleration of thrombosis upon discontinuation of heparin in Trousseau's Syndrome 4, 26, 62, 67 . Taken together with the relative inactivity of Vitamin K antagonists or direct thrombin inhibitors in some cases, it is reasonable to suggest that this heparin activity is mediated by more than just its ability to inactivate thrombin via enhancement of anti-thrombin. 
Heparin-mediated Interactions that are Potentially Beneficial in "Trousseau's Syndrome".
In addition to antithrombin, heparins also activate two other serpins involved in blood coagulation, Heparin cofactor II 72 and protein C inhibitor 73 . Another independent heparin action is to block the binding of L-and P-Selectins to their natural and pathological ligands 54, [74] [75] [76] . This interrupts carcinoma-mucin dependent adhesion phenomena mediated by these selectins (see figure) as well as signaling pathways triggered by their interactions with natural ligands (e.g., induction of tissue factor or platelet activating factor synthesis in monocytes by P-selectin engagement of PSGL-1) 77, 78 , which is one possible explanation for the subsequent generation of thrombin and fibrin. Meanwhile, Tissue Factor Pathway Inhibitor (TFPI) is released from the
endothelium by heparin, perhaps delivering higher concentrations of this potent anticoagulant to the sites of ongoing thrombosis [79] [80] [81] [82] [83] . The effects of heparin on fibrinolysis are more complex, as both activators and inhibitors can be affected 84, 85 . Heparin can also bind and potentially neutralize a wide variety of cytokines and chemokines [86] [87] [88] . Some of these inflammatory cytokines could potentially aggravate Trousseau's Syndrome by activating endothelial cells, causing enhanced expression of adhesion molecules, including P-selectin.
Alternative Approaches to the Management of "Trousseau's Syndrome". In recent years low molecular weight heparins (LMWHs) have become popular, in part because of their improved pharmacokinetics, the ability to give single daily dosages and the reduced incidence of heparininduced thrombocytopenia [89] [90] [91] . Moreover, LMWHs selectively inhibit factor Xa without affecting thrombin, and may be less likely to deplete TFPI pools over time 79, 80, 82, 92, 93 . Thus, there have been several reports in which LMWHs have been successfully substituted for unfractionated heparin in managing Trousseau's Syndrome 64, 94 . However, it should be noted that the ability of some LMWHs to mediate some of the heparin actions indicated in Figure 1 may not be equivalent. For example, some LMWHs of shorter length are not as effective at blocking P-and L-selectin, even at comparable levels of anti-Xa activity 55, 95 . Therefore, while switching to LMWHs may be convenient and even beneficial [96] [97] [98] , further studies are needed to assure that any useful effects are not being lost when using some of them. An interesting prediction arising from recent work is that the synthetic pentasaccharide Fondaparinux (Arixtra) might be least effective, even if given at doses that achieve equivalent anti-factor Xa activity 55 . This needs to be studied further. Of course, one can envisage an alternate approach, using a combination of modern anticoagulants agents 99 that would block many of the processes thought to be involved in
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Trousseau's Syndrome. However, as with any form of combination therapy there is an increased probability of side effects.
Risk of an Occult Cancer in a Patient with Unexplained Thrombosis. By its original
definition, the diagnosis of "Trousseau's Syndrome" is made in retrospect, when the occult malignancy is found. Thus, one can ask if there is any practical value in making a diagnosis of this syndrome. The risk of an occult carcinoma being found after an episode of otherwise unexplained venous thrombosis has ranged widely in various retrospective series. In a recent prospective analysis 100 , apparently cancer-free patients with acute idiopathic venous thromboembolism were randomized to either have extensive screening for occult cancer or to no further testing. In the former group about 13% of the patients were shown to have an occult cancer. A similar number of cancers emerged in the control group over a two-year period. As expected, malignancies found in the extensive screening group were at an earlier stage.
However, cancer-related mortality during the 2-year follow-up period was not markedly different. A subsequent decision analysis of this data suggested that screening for cancer with an abdominal/pelvic CT with or without mammography and/or sputum cytology appeared potentially useful for cancer screening in patients with unexplained thromboses 101 . Overall, the conclusions were that "the cost-effectiveness analysis of this strategy needs confirmation in a large trial" and that while "Data from these studies do not conclusively demonstrate that earlier diagnosis ultimately prolongs life…. the collective observation makes such a beneficial effect likely" 102 .
There are many features in common between the pathogenesis of Trousseau's Syndrome and factors that appear to facilitate tumor metastases, including roles for TF, selectins, platelets, endothelium, and fibrin [5] [6] [7] [8] 42, 60, [103] [104] [105] . Thus, it is likely that the thrombotic processes involved in 
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